Although understudied in breast cancer, mouse models and clinical trials in other solid tumours including renal cell carcinoma and melanoma have shown IL-10 inhibition upregulates anti-tumour CD8+ T cell responses and subsequently potentiates immunotherapy treatment [45]. The gene discussed is IL10; the disease is breast carcinoma.